Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
2006-04-04
2006-04-04
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
C514S574000, C424S647000, C424S648000
Reexamination Certificate
active
07022734
ABSTRACT:
The use of transition metal complexes in the treatment of septic shock, in particular the hypotension associated therewith and pharmaceutical formulations comprising such complexes are disclosed. The use of such transition metal complexes in the treatment of other conditions caused by pathological NO production are also disclosed.
REFERENCES:
patent: 2891854 (1959-06-01), Kroll et al.
patent: 5223538 (1993-06-01), Fridovich et al.
patent: 5227405 (1993-07-01), Fridovich et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 3842143 (1990-06-01), None
patent: 0097303 (1987-01-01), None
patent: 0401347 (1996-03-01), None
patent: WO 90/06768 (1990-06-01), None
patent: WO 93/16721 (1993-09-01), None
patent: WO 94/26263 (1994-11-01), None
Medline Abstract, AN 81004795, 1981, Kahn et al.
WPIDS Abstract, AN 92-010845, Aitken, R.J. et al. Abstract of GB 2245589 A, 1992.
HCAPLUS Abstract, AN 1984:123531, Jeffrey, G.C. et al., Abstract of EP 97303 A1 1984.
Littlejohn, D. et al., J. Phys. Chem., vol. 86, No. 4, pp. 537-540, 1982.
Kazmierski et al., “Iron chelates bind nitric oxide and decrease mortality in an experimental model of septic shock”, Aug. 1996, Proc. Natl. Acad. Sci USA, vol. 93, pp. 9138-9141.
Molina et al., “Efficacy of Treatment with Iron (III) Complex of Diethylenetriamine Pentaacetic Acid in Mice and Primates Inoculated with Live Lethal Dose 100Escherichia coli”, Jul. 1996, J. Clin Invest., The American Society for Clinical Investigation, Inc., 0021-9738/96/07/192/07, vol. 98, No. 1, pp. 192-198.
Mustard et al., “Deferoxamine Induces Hypotension in Experimental Gram-Negative Septicemia”, 1994, SHOCK, vol. 1, No. 3, pp. 221-227.
Sharpe et al., “Failure of therapy with 2,3-dihydroxybenzoic acid to modify the course of sepsis-induced lung injury”, 1990, The American Physiological Society, 0161-7567/90, pp. 1893-1902.
Boyce et al., “Life-Threatening Sepsis Complicating Heavy Metal Chelation Therapy with Desferrioxamine”, 1985, Aust NZ J Med., vol. 15, pp. 654-655.
Bezkorovainy, “Antimicrobial Properties of Iron-Binding Proteins”, Biochemistry Department, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, pp. 139-154.
Vulcano et al., “Deferoxamine reduces tissue injury and lethality in LPS-treated mice”, 2000, International Society fo Immunopharmcology, vol. 22, 0192-0561/00, pp. 635-644.
Mumby et al., “Is bleomycin-detectable iron present in the plasma of patients with septic shock?”, 1997, Intensive Care Med, vol. 23, pp. 635-639.
Moch et al., “Protective Effects of Hydroxyethyl Starch-Deferoxamine in Earky Sepsis”, 1995, SHOCK, vol. 4, No. 6, pp. 425-432.
Angstadt et al., “Other Hemoprotein- and Flavoprotein-Mediated Oxygenations: The Nitric Oxide Synthases”, Biotransformations: The Cytochrome P450, pp. 995-998.
Oury et al., “Cold-induced Brain Edema in Mice”, Jul. 1993, The Journal of Biological Chemistry, vol. 268, No.21, pp. 15394-15398.
Borman, “Iron chelates active against septic shock,” Sep. 1996 Chemical and Engineering News, vol. 39, pp. 15.
De Garavilla et al., “Novel Low-Molecular-Weight Superoxide Dismutase Mimic Deferoxamine-Manganese Improves Survival Following Hemorrhagic and Endotoxic”, 1992, Drug Development Research, vol. 25, pp. 139-148.
Kubrina et al., “Iron potentiates bacterial lopopolysaccharide-induced nitric oxide formation in animal organs”, 1993, Biochimca et. Biophysica Acta, vol. 1176, pp. 240-244.
Broner et al., “Reversal of Dopamine-refractory Septic Shock by Diethyldithiocarbamate, an Inhibitor of Endothelium-Derived Relaxing Factor”, 1993, Journal of Infectious Diseases, vol. 167, pp. 141-147.
Smith et al., “The effects of added dietary iron in various forms on mice inoculated withSalmonella typhimurium”, 1980, Research in Veterinary Science, vol. 28, pp. 161-167.
Sanan et al., “Desferrioxamine Mesylate 9Desferal) in Shock”, 1985, Pharmacos, vol. 28, pp. 103-105.
Ribeiro et al., “Reversible Binding of Nitric Oxide by a Salivary Heme Protein from a Bloodsucking Insect”, Apr. 1993, Science, vol. 260, pp. 539-541.
Weinberg, “Novel Uses of Deferoxamine”, 1990, The American Journal of Pediatric Hematology/Oncology, vol. 12, No. 1, pp. 9-13.
Bentur et al., “Deferoxamine (Desferrioxamine) New Toxicities for an Old Drug”, 1991, Drug Safety, vol. 6, No. 1, pp. 37-46.
Nagano et al., “Superoxide Dismutase Mimics Based on Iron in Vivo”, Jun. 1989, J Biol. Chem., vol. 264, No. 16, pp. 9243-9249.
Billiar et al., “Modulation of Nitrogen Oxide Synthesis in Vivo: NG-Monomethyl-L-Arginine Inhibits Endoxin-Induced Nitrite/Nitrite Biosynthesis While Promoting Hepatic Damage”, 1990, Journal of Leukocyte Biology, vol. 48, pp. 565-569.
Feierman et al., HCAPLUS Abstract, AN 1985:401978, “Ethanol oxidation by hydroxyl radicals: role of iron chelates, superoxide, and hydrogen peroxide”; pp. 1.
Budavari et al., “The Merck Index”, 11thEdition, 1989Merck and Co., Inc., Rahway, New Jersey, pp. 449.
Kazmierski Wieslaw Mieczyslaw
Molina Luis
Adams Stephanie D.
King & Spalding LLP
Knowles Sherry M.
Molichem Medicines, Inc.
Wang Shengjun
LandOfFree
Treatment of septic shock does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of septic shock, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of septic shock will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574367